drugset / Trial / NCT04334629
LIBERATE Trial in COVID-19
RandomizedParallel-groupDouble-blindTreatment
Summary
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
Timeline
- Start
- 2020-05-26
- Primary completion
- 2021-05-25
- Completion
- 2021-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibuprofen | Small molecule | 200 mg | — |